Subscribe
Subscribe for the Newsletter
Mobile Navigation
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Experience
Market Research
Directory
Close
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Company Info
Contact Clarity Pharmaceuticals
Clarity Pharmaceuticals
Clinical CRO
Overview
Contact US
Contributions
Contributors
Contributions
0 Contributors
1 / 0
No authors found
1 / 0
1 Contributions
1 / 1
Cu-67 SAR-bisPSMA
Clarity Receives US FDA Fast Track Designation for Treating Metastatic Castration-Resistant Prostate Cancer with Cu-67 SAR-bisPSMA
Clarity Pharmaceuticals
PR-02-25-NI-19
Feb 19, 2025
1 / 1
